Oxford BioTherapeutics (OBT), a portfolio company held across the Calculus VCT and Calculus EIS Funds, has entered into a multi-year collaboration with GSK to identify new antibody-based targets for cancer treatment. The agreement will use OBT’s proprietary OGAP®-Verify platform with the aim of discovering novel oncology targets suitable for immuno-oncology and Antibody Drug Conjugate (ADC) approaches.
Under the arrangement, early-stage discovery work will take place jointly, while GSK will lead subsequent development and commercialisation activities. OBT will receive an upfront payment and may receive further milestones and royalties connected to any successful commercial medicines.
This is the second major pharma collaboration announced by OBT during 2025, and follows a period of continued progress in applying the OGAP-Verify platform to identify highly specific cancer targets.
According to OBT, current treatments such as T-cell engagers and ADCs are promising but remain limited to a reduced proportion of eligible patients. The company believes greater target specificity may enable antibody-based therapies to reach wider groups of cancer patients over time.
For GSK, the partnership forms part of its ongoing focus on expanding oncology discovery capabilities, integrating external technologies with its internal development programmes.
The OGAP-Verify platform combines high-resolution proteomic analysis with target validation, supporting differentiated antibody development across solid tumours and haematological cancers.
OBT continues to progress its clinical-stage pipeline in parallel with partnership activity.